You are here

  • Home
  • Archive
  • Volume 13, Issue 1
  • Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic

Article Text

Article menu
Download PDFPDF
Letter
Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic

https://doi.org/10.1136/flgastro-2020-101760

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors JMG is lead author and designed the patient survey. AW led the initial service improvement and contributed to the article. SME supported the service development and contributed to the article. NK supported the service development and contributed to the article. CM supported the service development and contributed to the article. CC supported the service development and contributed to the article. GM was clinical lead for service development and is senior author.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.